DETERMINATION OF THE LEVEL OF CIRCULATING IMMUNE COMPLEXES IN PATIENTS WITH STABLE ANGINA DEPENDING ON THE FUNCTIONAL CLASS

Coronary artery atherosclerosis is one of the causes of coronary heart disease (CHD) and its chronic form – stable angina. Atherosclerosis can be considered as a chronic immune-inflammatory process in which antigenic stimuli originate from peroxide-modified lipoproteins. Literature data indicate the production of circulating immune complexes (CIC) containing lipoproteins as an antigen in patients with stable angina.
The aim of the study was to determine the content of CIC in patients with stable angina with functional classes (FC) I, II, III, IV.
Material and methods. The study was conducted in the Cardiology Department № 1 of the 6th Clinical Hospital of Minsk. The study included 141 patients with stable angina with functional classes (FC) I, II, III, IV, which made up 4 main study groups (A, B, C, D). The control group consisted of 30 practically healthy individuals of comparable age. The CIC was determined by the enzyme immunoassay method in the venous blood of patients. Statistical data processing was performed using the Statistica 10.0 program. At p < 0.05, the differences were considered statistically significant.
Results and discussion. In patients with angina pectoris FC I, the CIC level was 243.0 ± 31.4 conventional units. As the FC of stable angina pectoris increased, the CIC level also increased, which in patients with FC IV was 404.0 ± 52.4 conventional units.
Conclusion. With an increase in the severity of stable angina pectoris, the content of CIC statistically significantly increases, which indicates the development of an immunopathological process as coronary circulatory failure progresses.

1. Orekhov, A. N. Mechanisms of atherogenesis and development of antiatherosclerotic therapy / A. N. Orekhov // Current pharmaceutical design. – 2015. – Vol. 21, № 9. – Р. 1103–1106.

2. Stoll, L. L. Potential novel mechanisms for diabetesaccelerated atherosclerosis / L. L. Stoll, G. M. Denning, N. L. Weintraub // Current diabetes reports. – 2013. – Vol. 13, № 1. – S. 95–103.

3. Tsimikas, S. High-dose atorvastatin reduces systemic oxidative stress and inflammation: the atorvastatin on endothelial function (AEF) study / S. Tsimikas, J. L. Witztum, E. R. Miller [et al.] // Journal of the American College of Cardiology. – 2006. – Vol. 47, № 10. – S. 1986–1994.

4. Tsimikas, S. Oxidative modification-specific antibodies and lipoproteins in the diagnosis and prognosis of cardiovascular disease / S. Tsimikas // Antioxidants & redox signaling. – 2010. – Vol. 12, № 7. – S. 921–930.

5. Tsimikas, S. Assessment of oxidized lipids and lipoproteins in humans / S. Tsimikas // Journal of the American College of Cardiology. – 2017. – Vol. 69, № 10. – S. 1333–1345.

6. Tsimikas, S. Oxidized phospholipids, Lp(a), and coronaryartery disease / S. Tsimikas, E. S. Brilakis, E. R. Miller [et al.] // Arteriosclerosis, thrombosis and vascular biology. – 2005. – Vol. 25, № 4. – S. 835–841.

7. Tsimikas, S. Relationship of oxidation-specific epitopes to biomarkers of lipid metabolism, inflammation, renal function, and clinical events / S. Tsimikas, P. Clopton, E. S. Brilakis [et al.] // Journal of the American College of Cardiology. – 2006. – Vol. 48, № 7. – S. 1458–1467.

8. Levina, L. I. Autoimmunnye reakcii gumoral'nogo i kletochnogo tipa u bol'nyh s razlichnymi formami stenokardii / L. I. Levina, A. B. Shapovalova // Vestnik Sankt-Peterburgskogo universiteta. Medicina. – 2007. – № 4. – S. 15–19.

9. Shcheglov, D. S. Vliyanie dislipidemii na pokazateli kletochnogo i gumoral'nogo immuniteta u bol'nyh so stabil'noj stenokardiej / D. S. Shcheglov, I. P. Dudanov, L. V. Shcheglova, M. V. Avdeeva // Medicinskij akademicheskij zhurnal. – 2016. – Vol. 16, № 3. – S. 29–34.